Article Text
PDF
Statistics from Altmetric.com
Q In patients with asthma, is the addition of salmeterol to usual pharmacotherapy safe?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★★☆ Respirology ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Salmeterol Multicenter Asthma Research Trial [SMART]).
Allocation:
{concealed}*.†
Blinding:
blinded (patients, healthcare providers, {data collectors}*, outcome assessors, and {data analysts}*).†
Follow up period:
28 weeks.
Setting:
6163 sites in the US.
Patients:
26 355 patients ⩾12 years of age (mean age 39 y, 63% women) who were diagnosed with asthma and currently receiving prescription asthma medication. Exclusion criteria included previous use of inhaled long acting β2 agonists and history of adverse reactions to sympathomimetic amine drugs.
Intervention:
salmeterol, 42 μg, twice daily (on arising and before bed) …
Footnotes
-
↵* Information provided by author.
-
↵‡ GSK Clinical Trials Registry. http://ctr.glaxowellcome.co.uk/Summary/salmeterol/studylist.asp (SLGA5011 SMART) (accessed 24 Jul 06).
-
For correspondence: Dr P M Dorinsky, GlaxoSmithKline, Research Triangle Park, NC, USA. Paul.m.dorinsky{at}gsk.com
-
Source of funding: GlaxoSmithKline.
Linked Articles
- Glossary